Navigation Links
CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
Date:9/17/2007

VIENNA, Va., Sept. 17 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX: CVM) announces that its Chief Executive Officer, Geert Kersten, is a featured presenter at the Biotech/Pharma/Healthcare On-line Forum. The webcast presentation is scheduled for Tuesday, September 18, 2007 at 9:30 a.m. (Eastern Daylight Time) and can be accessed via the Internet at CEL-SCI's website http://www.cel-sci.com or http://www.investorcalendar.com/ClientPage.asp?ID=119627. If you are unable to participate during the live webcast, the call will be available for replay.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R). In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/13/2017)... York City-based market research firm Kalorama Information notes seven trends ... new products to new costs, to the threat of generic ... Potential Pipeline Disruptors . Among them are ... Age-Driven Growth - True Impact Moment Arriving   ... growing population and, to a more extreme extent, the aging ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... , ... Kevin Harrington, one of the original Sharks from hit reality series Shark Tank, and ... campaign with My Real Earth. , Most people put their healthcare above their skincare, but ... what we put in our bodies. After all, the skin is the largest organ which ...
(Date:7/28/2017)... , ... July 28, 2017 , ... Join Becker's Healthcare ... 21 - 23, 2017 in Chicago IL. Great sessions on Epic, Cyber Security, Telehealth, ... , Don't miss discussion talks by:, George W. Bush, ...
(Date:7/28/2017)... , ... July 28, 2017 , ... Leyden Insurance Agency, ... and business owners in and around Cook County, is working in conjunction with the ... students and veterans. , Established in honor of a brave soldier who is still ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. Adam Kimowitz, respected ... Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination in Chicago, IL, ... implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, practice at their ...
(Date:7/27/2017)... ... July 27, 2017 , ... For bicycling enthusiasts around ... challenge. The 24-hour race takes place against a backdrop of tree-lined hills at the ... run from July 28-30, Rad am Ring consists of some 73 curves, stretching out ...
Breaking Medicine News(10 mins):